Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?

被引：12
|
作者：
Jain, Preetesh [1 ]
Ok, Chi Young [1 ]
Konoplev, Sergej [1 ]
Patel, Keyur P. [1 ]
Jorgensen, Jeffrey [1 ]
Estrov, Zeev [1 ]
Luthra, Raja [1 ]
Kantarjian, Hagop [1 ]
Ravandi, Farhad [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 07期
关键词：
MUTATIONS; V600E; ASSAY;
D O I：
10.1200/JCO.2013.50.9661
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E57 / E60
页数：4
相关论文
共 36 条
  • [1] BRAF-negative, CD103-negative hairy cell leukemia
    Jimenez, Adam
    Shuai, Wen
    BLOOD, 2023, 141 (07) : 806 - 806
  • [2] Ibrutinib for relapsed refractory hairy cell leukemia variant
    Bohn, Jan-Paul
    Wanner, David
    Steurer, Michael
    LEUKEMIA & LYMPHOMA, 2017, 58 (05) : 1224 - 1226
  • [3] Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation
    Xi, Liqiang
    Arons, Evgeny
    Navarro, Winnifred
    Calvo, Katherine R.
    Stetler-Stevenson, Maryalice
    Raffeld, Mark
    Kreitman, Robert J.
    BLOOD, 2012, 119 (14) : 3330 - 3332
  • [4] Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia
    Tiacci, E.
    Park, J. H.
    De Carolis, L.
    Chung, S. S.
    Broccoli, A.
    Scott, S.
    Zaja, F.
    Devlin, S.
    Pulsoni, A.
    Chung, Y. R.
    Cimminiello, M.
    Kim, E.
    Rossi, D.
    Stone, R. M.
    Motta, G.
    Saven, A.
    Varettoni, M.
    Altman, J. K.
    Anastasia, A.
    Grever, M. R.
    Ambrosetti, A.
    Rai, K. R.
    Fraticelli, V.
    Lacouture, M. E.
    Carella, A. M.
    Levine, R. L.
    Leoni, P.
    Rambaldi, A.
    Falzetti, F.
    Ascani, S.
    Capponi, M.
    Martelli, M. P.
    Park, C. Y.
    Pileri, S. A.
    Rosen, N.
    Foa, R.
    Berger, M. F.
    Zinzani, P. L.
    Abdel-Wahab, O.
    Falini, B.
    Tallman, M. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (18): : 1733 - 1747
  • [5] How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors
    Falini, Brunangelo
    De Carolis, Luca
    Tiacci, Enrico
    BLOOD, 2022, 139 (15) : 2294 - 2305
  • [6] Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax
    Jain, Preetesh
    Kanagal-Shamanna, Rashmi
    Konoplev, Sergej
    Zuo, Zhuang
    Estrov, Zeev
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (12) : 1568 - 1569
  • [7] Variant B Cell Receptor Isotype Functions Differ in Hairy Cell Leukemia with Mutated BRAF and IGHV Genes
    Weston-Bell, Nicola J.
    Forconi, Francesco
    Kluin-Nelemans, Hanneke C.
    Sahota, Surinder S.
    PLOS ONE, 2014, 9 (01):
  • [8] Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia
    Park, Jae H.
    Chung, Stephen S.
    Chung, Young Rock
    Won, Helen
    Teruya-Feldstein, Julie
    Berger, Michael
    Khawaja, Talal T.
    Lacouture, Mario E.
    Levine, Ross L.
    Abdel-Wahab, Omar
    Tallman, Martin S.
    BLOOD, 2013, 122 (21)
  • [9] Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia
    Andritsos, Leslie A.
    Grieselhuber, Nicole R.
    Anghelina, Mirela
    Rogers, Kerry A.
    Roychowdhury, Sameek
    Reeser, Julie W.
    Timmers, Cynthia D.
    Freud, Aharon G.
    Blachly, James S.
    Lucas, David M.
    Lozanski, Gerard
    Jones, Jeffrey A.
    Williams, Katie
    Oakes, Christopher
    Jones, Dan
    Grever, Michael R.
    LEUKEMIA & LYMPHOMA, 2018, 59 (04) : 1008 - 1011
  • [10] Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia
    Andritsos, Leslie A.
    Anghelina, Mirela
    Grieselhuber, Nicole R.
    Roychowdhury, Sameek
    Reeser, Julie
    Timmers, Cynthia
    Freud, Aharon G.
    Blachly, James S.
    Lucas, David M.
    Lozanski, Gerard
    Jones, Jeffrey
    Rogers, Kerry A.
    Zhao, Weiqiang
    Grever, Michael R.
    BLOOD, 2016, 128 (22)
1234